Creative Biolabs Introduces NHC and Nelfinavir-related COVID-19 Drug Discovery Services

Creative Biolabs Introduces NHC and Nelfinavir-related COVID-19 Drug Discovery Services
With the ace expert team and first-in-class technological platforms, Creative Biolabs introduces one-stop SARS-CoV-2 antiviral drug discovery services on 2 candidates, beta-D-N4-hydroxycytidine (NHC) and Nelfinavir (Viracept).

Since the end of 2019, COVID-19 has caused widespread mortality, leading to an unprecedented challenge to economic and social disruption, creating an urgent need for effective treatments and a long-term need for antivirals for future emergent coronaviruses. 

With an unrelenting drive in biotech research and industry, Creative Biolabs had previously conducted extensive and in-depth research on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome-associated Coronavirus (SARS-CoV). Relying on the mature drug and vaccine development technology and experience, since the outbreak of COVID-19, Creative Biolabs has quickly organized the scientist team to develop various SARS-CoV-2-related products, such as recombinant proteins, antibodies, and test kits, as well as the one-stop drug discovery and vaccine development services.

Creative Biolabs spares no effort to update its SARS-CoV-2 drug development services and now offers tailored services on beta-D-N4-hydroxycytidine (NHC) and Nelfinavir for the treatment of SARS-CoV-2.

Beta-D-N4-hydroxycytidine (NHC) for SARS-CoV-2 Antiviral Drug Discovery

Studies have shown that NHC has broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, etc., and mouse models of SARS and MERS demonstrated that early treatment reduced viral replication and damage to the lungs.

Despite the previous research found it a potential candidate, its antiviral mechanism of action is not completely uncovered. To help fill the gaps in this field, Creative Biolabs provides NHC-related SARS-CoV-2 drug discovery service with a customized proposal to meet any project requirement in the quality, timeline, and budget.

Nelfinavir (Viracept) for SARS-CoV-2Antiviral Drug Discovery

Scientists have also discovered that Nelfinavir, a protease inhibitor approved for the treatment of HIV infection in 1997, exhibits strong activity in inhibiting SARS-CoV in vitro, indicating that it may also have good therapeutic performance for SARS-CoV-2.

Creative Biolabs has devoted great attention to the development of antiviral protease inhibitors. Analyzing the crystal structure of existing commercial drugs can help clients determine and evaluate whether Nelfinavir has potential as an effective antiviral agent against SARS-CoV-2 and how it works.

“As the whole world is working on the COVID-19 drug development, we also would like to devote ourselves to this fight with coronavirus. We keep catching up on related research and updating our services. For example, SARS-CoV-2-specific short interfering RNA inhibitors recently exemplify a powerful new means, so we integrated siRNA drug development platform to provide a total solution for siRNA therapeutics discovery and development, from siRNA design, synthesis to preclinical tests.”

More information about coronavirus-related vaccine and drug discovery services, IVD immunoassays as well as a wide range of products can be found on

About Creative Biolabs

Empowered by leading technology and years of experience in biomedical science, Creative Biolabs has successfully accomplished numerous challenging projects for customers in requirements with accumulated experience in drug discovery and vaccine development. Especially in the field of antiviral drugs and vaccines, Creative Biolabs provides drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic services at the world-leading level.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Country: United States